+357 96 030922
info@marketpublishers.com

Global Oral Weight Loss Drug Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GAA87163A4B4EN.html
Date: September 2026
Pages: 141
Price: US$ 4,480.00 (Single User License)
ID: GAA87163A4B4EN

Abstracts

The global Oral Weight Loss Drug market size is expected to reach $ 23206 million by 2032, rising at a market growth of 28.0% CAGR during the forecast period (2026-2032).

The Oral Weight Loss Drug market covers pharmaceutical products formulated for oral administration and developed for body-weight reduction, obesity treatment, and long-term weight management. The research scope comprises marketed and investigational tablets, immediate-release and extended-release tablets, hard capsules, extended-release capsules, and other oral solid dosage forms. Products are differentiated by mechanisms including GLP-1 receptor agonism, dual GLP-1/GIP receptor agonism, gastrointestinal lipase inhibition, sympathomimetic appetite suppression, central appetite and reward-pathway modulation, MGAT2 inhibition, and other metabolic pathways. Both single-ingredient drugs and fixed-dose combinations are covered, together with originator and branded products, generic drugs, and investigational candidates. Principal clinical applications include adult obesity, overweight accompanied by weight-related comorbidities, adolescent obesity, obesity associated with type 2 diabetes, short-term weight reduction, long-term chronic weight management, and weight maintenance following initial treatment. The market is evaluated according to therapeutic mechanism, formulation, clinical positioning, regulatory status, patient population, treatment duration, and commercialization model.

Key Findings

The average gross profit margin of this product is 75%

Oral GLP-1 therapies are reshaping the overall product mix

+357 96 030922
info@marketpublishers.com

Legacy small molecules retain relevance in cost-sensitive treatment pathways

Once-daily tablets broaden options beyond injectable obesity treatment

North America leads commercialization of next-generation oral therapies

Safety tolerability and persistence determine long-term market value

Market Trends

The Oral Weight Loss Drug market is entering a structural transition from conventional appetite suppressants, gastrointestinal lipase inhibitors, and fixed-dose central nervous system combinations toward incretin-based oral therapies and other metabolically targeted small molecules. The approval and commercialization of once-daily oral semaglutide and orforglipron in the United States have demonstrated that oral products can provide clinically meaningful chronic weight-management options within a therapeutic field previously transformed by injectable GLP-1 products. Product development is now following two principal technical routes: peptide-based tablets supported by specialized absorption-enhancing formulations and non-peptide small-molecule receptor agonists designed for conventional oral administration. At the same time, development programs targeting dual receptors, intestinal lipid metabolism, appetite regulation, and combination mechanisms are widening the innovation pipeline. Customer demand is also moving away from temporary weight reduction toward sustained obesity management, maintenance of treatment response, and management of cardiometabolic comorbidities. Consequently, differentiation increasingly depends on efficacy, gastrointestinal tolerability, dosing flexibility, food-related administration requirements, treatment persistence, and evidence supporting broader metabolic benefits rather than weight loss alone.

Market Dynamics

Drivers

The principal demand driver is the expanding population affected by obesity and overweight-related metabolic disorders, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, and other chronic conditions. Obesity is

+357 96 030922
info@marketpublishers.com

increasingly managed as a long-duration disease rather than a short-term lifestyle issue, supporting recurring pharmacological treatment and weight-maintenance demand. Oral dosage forms may broaden the addressable patient population by reducing injection-related barriers, fitting established retail-pharmacy and primary-care workflows, and offering patients a familiar administration format. The emergence of oral therapies with stronger weight-reduction profiles has also increased physician and patient interest in pharmaceutical intervention. Regulatory recognition of chronic weight management and broader cardiometabolic outcomes is encouraging investment in differentiated oral mechanisms, while competition among pharmaceutical groups is accelerating clinical development, manufacturing scale-up, and commercial education. These factors collectively support expansion across newly treated patients, individuals switching from older oral agents, and patients seeking alternatives to injectable therapy.

Restraints

Market development remains constrained by safety, tolerability, access, and treatment-persistence issues. Gastrointestinal adverse reactions, gradual dose-escalation requirements, contraindications, drug interactions, and mechanism-specific warnings may restrict product suitability or result in discontinuation. Some older oral therapies offer moderate weight-loss efficacy relative to newer incretin-based products, while innovative therapies may face affordability and reimbursement barriers that limit penetration among cost-sensitive populations. Oral administration does not automatically eliminate adherence challenges because patients must continue treatment over extended periods, comply with dietary and physical-activity recommendations, and follow product-specific dosing instructions. Peptide tablets may also require technically demanding formulation and administration conditions, while novel small molecules must establish durable efficacy and acceptable long-term safety. Uneven insurance coverage and differences in national obesity-treatment policies further create a gap between clinical eligibility and actual commercial access.

Opportunities

The most significant opportunity lies in expanding oral pharmacotherapy from a limited selection of legacy agents into a broader portfolio of high-efficacy chronic weight-management products. Small-molecule GLP-1 receptor agonists provide potential advantages in manufacturing scalability, storage, transportation, and administration flexibility, while peptide tablets create opportunities to extend established incretin platforms into needle-free formats. Additional potential exists in GLP-1/GIP dual

+357 96 030922
info@marketpublishers.com

receptor agonists, MGAT2 inhibitors, differentiated appetite-regulation pathways, and fixed-dose combinations designed to improve efficacy or address multiple metabolic mechanisms. Products optimized for patients with type 2 diabetes, cardiovascular risk, or other weight-related comorbidities may generate greater clinical value than products positioned only for general weight reduction. Further opportunities are expected in adolescent obesity, long-term weight maintenance, emerging markets with limited access to injectable therapies, and lower-cost generic or differentiated branded products. Companies capable of balancing efficacy, tolerability, dosing convenience, and affordability are positioned to reach patient groups not adequately served by current treatment options.

Challenges

Long-term commercial success will require more than demonstrating statistically significant weight reduction. Developers must establish clinically meaningful differentiation against rapidly improving oral and injectable standards of care, while generating sufficient evidence on treatment durability, safety, discontinuation effects, cardiometabolic outcomes, and use in diverse patient groups. Clinical trials are increasingly expensive and complex as regulators, physicians, and payers seek longer follow-up and broader outcome measures. Companies must also manage large-scale active ingredient production, formulation consistency, quality control, and demand forecasting without compromising regulatory compliance. Competitive intensity may shorten product differentiation cycles and increase marketing, patient-support, and contracting expenditure. Meanwhile, public concern regarding inappropriate cosmetic use, unapproved compounded products, adverse-event management, and unequal access may lead to additional regulatory scrutiny. The market therefore presents substantial demand potential but also requires sustained clinical investment, manufacturing discipline, and carefully managed commercialization.

Industry Chain Analysis

The upstream chain of the Oral Weight Loss Drug market comprises peptide and small-molecule active pharmaceutical ingredients, chemical intermediates, absorption-enhancing agents, release-controlling materials, pharmaceutical-grade excipients, capsule shells, and packaging materials. Technical requirements differ significantly by mechanism. Oral peptide products require specialized formulation strategies to protect active ingredients and improve gastrointestinal absorption, whereas non-peptide small

+357 96 030922
info@marketpublishers.com

molecules depend more heavily on medicinal chemistry optimization, scalable synthesis, impurity control, and conventional solid-dose manufacturing. Fixed-dose combinations and extended-release products additionally require compatibility studies and release-profile control. The availability, quality, regulatory status, and cost of active ingredients therefore have a direct influence on manufacturing economics and supply reliability.

Midstream activities cover formulation development, tablet compression or capsule filling, coating, analytical testing, clinical development, regulatory registration, commercial manufacturing, and pharmacovigilance. Downstream value is realized through hospitals, specialist clinics, primary-care providers, retail and specialty pharmacies, digital weight-management platforms, and structured chronic-care programs. Innovative originator products capture value through differentiated clinical evidence, intellectual property, brand recognition, and physician adoption, while established brands and generic products compete more strongly through manufacturing efficiency, pricing, channel coverage, and patient accessibility. Across the value chain, the highest barriers are concentrated in mechanism validation, late-stage clinical development, regulatory approval, scalable formulation, and evidence generation supporting long-term treatment value.

Segment Insights

By therapeutic mechanism, GLP-1 receptor agonists have become the most strategically important innovation segment because they narrow the efficacy gap between oral and injectable obesity therapies. Within this category, peptide tablets and small-molecule agonists represent distinct technological and commercial models. Peptide-based products benefit from established incretin biology but require sophisticated absorption technology, while small molecules may provide greater administration flexibility and conventional manufacturing potential. GLP-1/GIP dual receptor agonists and other multi-pathway products represent an emerging development direction, although clinical differentiation and safety remain decisive. Gastrointestinal lipase inhibitors, sympathomimetic appetite suppressants, naltrexone/bupropion combinations, and phentermine/topiramate combinations retain market relevance through established prescribing experience, generic availability, or differentiated patient suitability.

By product class, single-ingredient drugs provide clearer mechanism positioning and simpler clinical evaluation, whereas fixed-dose combinations seek complementary

+357 96 030922
info@marketpublishers.com

effects through multiple pathways. Originator and branded products account for most innovation value, while generic drugs serve price-sensitive and access-constrained markets. Investigational drugs form an increasingly diverse pipeline covering receptor agonism, intestinal lipid metabolism, and central appetite control. From a dosage-form perspective, immediate-release tablets provide manufacturing simplicity, while extended-release tablets and capsules support controlled exposure and may improve dosing convenience for selected mechanisms. Competitive advantage within each segment will depend on the balance between weight reduction, tolerability, administration requirements, treatment persistence, and total patient cost.

Downstream Market Opportunities

Adult obesity and overweight accompanied by weight-related comorbidities constitute the principal clinical opportunity for Oral Weight Loss Drug products. Within this population, patients with type 2 diabetes, cardiovascular risk factors, dyslipidemia, hypertension, or other metabolic complications may derive particular value from therapies that address both body weight and broader metabolic outcomes. Long-term chronic weight management and maintenance following initial weight reduction are becoming more important than episodic treatment, increasing demand for products with acceptable tolerability and convenient daily administration. Adolescent obesity represents an additional opportunity, although regulatory requirements, safety considerations, and family-supported adherence are more demanding. Oral products may also expand treatment among patients unwilling or unable to use injectable drugs and in healthcare systems where pharmacy-based distribution and primary-care management are more scalable than specialist-led injection programs.

Regional Insights

North America currently represents the most commercially advanced market for next-generation Oral Weight Loss Drug products, supported by early regulatory approvals, established obesity-treatment channels, substantial patient awareness, and rapid commercialization of oral GLP-1 therapies. The United States became the first major market to approve and launch once-daily oral semaglutide for weight management, followed by approval of the small-molecule GLP-1 receptor agonist orforglipron in 2026. This early market access provides important evidence regarding prescription uptake, patient segmentation, pricing, persistence, and competition with injectable products.

+357 96 030922
info@marketpublishers.com

Europe offers meaningful demand but is more strongly influenced by health-technology assessment, national reimbursement decisions, prescribing controls, and differences among healthcare systems. Asia-Pacific represents an important longer-term opportunity due to a large population affected by obesity and metabolic disease, expanding domestic drug-development activity, and demand for more accessible oral treatment. China is developing into both a clinical-development base and a potential commercialization market for innovative oral mechanisms, although pricing, reimbursement, regulatory differentiation, and physician education will shape adoption. In other regions, market expansion will depend on affordability, diagnosis rates, healthcare access, and the ability of suppliers to establish reliable local distribution.

Competitive Landscape Analysis

The competitive landscape is transitioning from a relatively established market of gastrointestinal lipase inhibitors, appetite suppressants, and fixed-dose combination products into a broader innovation race involving oral incretin therapies and new metabolic mechanisms. Novo Nordisk and Eli Lilly have established early commercial positions in next-generation oral GLP-1 treatment through approved once-daily products, raising expectations for efficacy and chronic-treatment value. Established oral brands continue to compete through physician familiarity, lower treatment costs, generic availability, and defined patient niches. At the same time, diversified pharmaceutical groups and clinical-stage biotechnology companies in the confirmed participant set are advancing oral GLP-1 receptor agonists, dual receptor candidates, MGAT2 inhibitors, and other mechanism-based products. Competitive positioning is therefore becoming multi-dimensional: leading companies require clinical efficacy and safety data, scalable manufacturing, regulatory execution, reimbursement access, brand credibility, and patient-support capabilities. Companies with less differentiated efficacy may compete through tolerability, flexible administration, combination strategies, regional pricing, or access advantages. As additional candidates progress, head-to-head evidence and real-world treatment persistence are expected to become increasingly important determinants of commercial positioning.

Report Scope

This report studies the global Oral Weight Loss Drug demand, key companies, and key regions.

+357 96 030922
info@marketpublishers.com

This report is a detailed and comprehensive analysis of the world market for Oral Weight Loss Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oral Weight Loss Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Oral Weight Loss Drug total market, 2021-2032, (USD Million)

Global Oral Weight Loss Drug total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Oral Weight Loss Drug total market, key domestic companies, and share, (USD Million)

Global Oral Weight Loss Drug revenue by player, revenue and market share 2021-2026, (USD Million)

Global Oral Weight Loss Drug total market by Type, CAGR, 2021-2032, (USD Million)

Global Oral Weight Loss Drug total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Oral Weight Loss Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Currax Pharmaceuticals, VIVUS, Roche, Structure Therapeutics, Viking Therapeutics, Terns Pharmaceuticals, AstraZeneca, Merck & Co, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Oral Weight Loss Drug market

+357 96 030922
info@marketpublishers.com

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Oral Weight Loss Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Oral Weight Loss Drug Market, Segmentation by Type:

GLP-1 Receptor Agonists

Gastrointestinal Lipase Inhibitors

Sympathomimetic Appetite Suppressants

+357 96 030922
info@marketpublishers.com

Naltrexone/Bupropion Combination Drugs

Other

Global Oral Weight Loss Drug Market, Segmentation by Ingredient:

Single-Ingredient Drugs

Fixed-Dose Combination Drugs

Global Oral Weight Loss Drug Market, Segmentation by Dosage Form:

Immediate-Release Tablets

Extended-Release Tablets

Hard Capsules

Extended-Release Capsules

Other

Global Oral Weight Loss Drug Market, Segmentation by Application:

dult Obesity

Adolescent Obesity

Short-Term Weight Reduction

Long-Term Chronic Weight Management

Other

+357 96 030922
info@marketpublishers.com

Companies Profiled:

Novo Nordisk

Eli Lilly

Currax Pharmaceuticals

VIVUS

Roche

Structure Therapeutics

Viking Therapeutics

Terns Pharmaceuticals

AstraZeneca

Merck & Co

Jiangsu Hengrui Pharmaceuticals

Huadong Medicine

Innovent Biologics

Ascletis Pharma

Hansoh Pharmaceutical

Kailera Therapeutics

Shionogi & Co

Haleon

+357 96 030922
info@marketpublishers.com

Key Questions Answered

1. How big is the global Oral Weight Loss Drug market?
2. What is the demand of the global Oral Weight Loss Drug market?
3. What is the year over year growth of the global Oral Weight Loss Drug market?
4. What is the total value of the global Oral Weight Loss Drug market?
5. Who are the Major Players in the global Oral Weight Loss Drug market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Oral Weight Loss Drug Introduction
1.2 World Oral Weight Loss Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Oral Weight Loss Drug Total Market by Region (by Headquarter Location)
  1.3.1 World Oral Weight Loss Drug Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.3 China Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.4 Europe Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.5 Japan Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.6 South Korea Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.7 ASEAN Based Company Oral Weight Loss Drug Revenue (2021-2032)
  1.3.8 India Based Company Oral Weight Loss Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Oral Weight Loss Drug Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Oral Weight Loss Drug Consumption Value (2021-2032)
2.2 World Oral Weight Loss Drug Consumption Value by Region
  2.2.1 World Oral Weight Loss Drug Consumption Value by Region (2021-2026)
  2.2.2 World Oral Weight Loss Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Oral Weight Loss Drug Consumption Value (2021-2032)
2.4 China Oral Weight Loss Drug Consumption Value (2021-2032)
2.5 Europe Oral Weight Loss Drug Consumption Value (2021-2032)
2.6 Japan Oral Weight Loss Drug Consumption Value (2021-2032)
2.7 South Korea Oral Weight Loss Drug Consumption Value (2021-2032)
2.8 ASEAN Oral Weight Loss Drug Consumption Value (2021-2032)
2.9 India Oral Weight Loss Drug Consumption Value (2021-2032)

3 WORLD ORAL WEIGHT LOSS DRUG COMPANIES COMPETITIVE ANALYSIS

3.1 World Oral Weight Loss Drug Revenue by Player (2021-2026)

+357 96 030922
info@marketpublishers.com

3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oral Weight Loss Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oral Weight Loss Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Oral Weight Loss Drug in 2025
3.3 Oral Weight Loss Drug Company Evaluation Quadrant
3.4 Oral Weight Loss Drug Market: Overall Company Footprint Analysis
3.4.1 Oral Weight Loss Drug Market: Region Footprint
3.4.2 Oral Weight Loss Drug Market: Company Product Type Footprint
3.4.3 Oral Weight Loss Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Oral Weight Loss Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oral Weight Loss Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Oral Weight Loss Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Oral Weight Loss Drug Consumption Value Comparison
4.2.1 United States VS China: Oral Weight Loss Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oral Weight Loss Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Oral Weight Loss Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Oral Weight Loss Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oral Weight Loss Drug Revenue, (2021-2026)
4.4 China Based Companies Oral Weight Loss Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Oral Weight Loss Drug Companies, Company Headquarters (Province, Country)

+357 96 030922
info@marketpublishers.com

4.4.2 China Based Companies Oral Weight Loss Drug Revenue, (2021-2026)
4.5 Rest of World Based Oral Weight Loss Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Oral Weight Loss Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Oral Weight Loss Drug Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Oral Weight Loss Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 GLP-1 Receptor Agonists
5.2.2 Gastrointestinal Lipase Inhibitors
5.2.3 Sympathomimetic Appetite Suppressants
5.2.4 Naltrexone/Bupropion Combination Drugs
5.2.5 Other
5.3 Market Segment by Type
5.3.1 World Oral Weight Loss Drug Market Size by Type (2021-2026)
5.3.2 World Oral Weight Loss Drug Market Size by Type (2027-2032)
5.3.3 World Oral Weight Loss Drug Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY INGREDIENT

6.1 World Oral Weight Loss Drug Market Size Overview by Ingredient: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Ingredient
6.2.1 Single-Ingredient Drugs
6.2.2 Fixed-Dose Combination Drugs
6.3 Market Segment by Ingredient
6.3.1 World Oral Weight Loss Drug Market Size by Ingredient (2021-2026)
6.3.2 World Oral Weight Loss Drug Market Size by Ingredient (2027-2032)
6.3.3 World Oral Weight Loss Drug Market Size Market Share by Ingredient (2027-2032)

7 MARKET ANALYSIS BY DOSAGE FORM

7.1 World Oral Weight Loss Drug Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032

+357 96 030922
info@marketpublishers.com

7.2 Segment Introduction by Dosage Form
7.2.1 Immediate-Release Tablets
7.2.2 Extended-Release Tablets
7.2.3 Hard Capsules
7.2.4 Extended-Release Capsules
7.2.5 Other
7.3 Market Segment by Dosage Form
7.3.1 World Oral Weight Loss Drug Market Size by Dosage Form (2021-2026)
7.3.2 World Oral Weight Loss Drug Market Size by Dosage Form (2027-2032)
7.3.3 World Oral Weight Loss Drug Market Size Market Share by Dosage Form (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Oral Weight Loss Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 dult Obesity
8.2.2 Adolescent Obesity
8.2.3 Short-Term Weight Reduction
8.2.4 Long-Term Chronic Weight Management
8.2.5 Other
8.3 Market Segment by Application
8.3.1 World Oral Weight Loss Drug Market Size by Application (2021-2026)
8.3.2 World Oral Weight Loss Drug Market Size by Application (2027-2032)
8.3.3 World Oral Weight Loss Drug Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Novo Nordisk
9.1.1 Novo Nordisk Details
9.1.2 Novo Nordisk Major Business
9.1.3 Novo Nordisk Oral Weight Loss Drug Product and Services
9.1.4 Novo Nordisk Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novo Nordisk Recent Developments/Updates
9.1.6 Novo Nordisk Competitive Strengths & Weaknesses
9.2 Eli Lilly

+357 96 030922
info@marketpublishers.com

9.2.1 Eli Lilly Details
9.2.2 Eli Lilly Major Business
9.2.3 Eli Lilly Oral Weight Loss Drug Product and Services
9.2.4 Eli Lilly Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Eli Lilly Recent Developments/Updates
9.2.6 Eli Lilly Competitive Strengths & Weaknesses
9.3 Currax Pharmaceuticals
9.3.1 Currax Pharmaceuticals Details
9.3.2 Currax Pharmaceuticals Major Business
9.3.3 Currax Pharmaceuticals Oral Weight Loss Drug Product and Services
9.3.4 Currax Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Currax Pharmaceuticals Recent Developments/Updates
9.3.6 Currax Pharmaceuticals Competitive Strengths & Weaknesses
9.4 VIVUS
9.4.1 VIVUS Details
9.4.2 VIVUS Major Business
9.4.3 VIVUS Oral Weight Loss Drug Product and Services
9.4.4 VIVUS Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 VIVUS Recent Developments/Updates
9.4.6 VIVUS Competitive Strengths & Weaknesses
9.5 Roche
9.5.1 Roche Details
9.5.2 Roche Major Business
9.5.3 Roche Oral Weight Loss Drug Product and Services
9.5.4 Roche Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Roche Recent Developments/Updates
9.5.6 Roche Competitive Strengths & Weaknesses
9.6 Structure Therapeutics
9.6.1 Structure Therapeutics Details
9.6.2 Structure Therapeutics Major Business
9.6.3 Structure Therapeutics Oral Weight Loss Drug Product and Services
9.6.4 Structure Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Structure Therapeutics Recent Developments/Updates
9.6.6 Structure Therapeutics Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

9.7 Viking Therapeutics
9.7.1 Viking Therapeutics Details
9.7.2 Viking Therapeutics Major Business
9.7.3 Viking Therapeutics Oral Weight Loss Drug Product and Services
9.7.4 Viking Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Viking Therapeutics Recent Developments/Updates
9.7.6 Viking Therapeutics Competitive Strengths & Weaknesses
9.8 Terns Pharmaceuticals
9.8.1 Terns Pharmaceuticals Details
9.8.2 Terns Pharmaceuticals Major Business
9.8.3 Terns Pharmaceuticals Oral Weight Loss Drug Product and Services
9.8.4 Terns Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Terns Pharmaceuticals Recent Developments/Updates
9.8.6 Terns Pharmaceuticals Competitive Strengths & Weaknesses
9.9 AstraZeneca
9.9.1 AstraZeneca Details
9.9.2 AstraZeneca Major Business
9.9.3 AstraZeneca Oral Weight Loss Drug Product and Services
9.9.4 AstraZeneca Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 AstraZeneca Recent Developments/Updates
9.9.6 AstraZeneca Competitive Strengths & Weaknesses
9.10 Merck & Co
9.10.1 Merck & Co Details
9.10.2 Merck & Co Major Business
9.10.3 Merck & Co Oral Weight Loss Drug Product and Services
9.10.4 Merck & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Merck & Co Recent Developments/Updates
9.10.6 Merck & Co Competitive Strengths & Weaknesses
9.11 Jiangsu Hengrui Pharmaceuticals
9.11.1 Jiangsu Hengrui Pharmaceuticals Details
9.11.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.11.3 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product and Services
9.11.4 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.11.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.12 Huadong Medicine
9.12.1 Huadong Medicine Details
9.12.2 Huadong Medicine Major Business
9.12.3 Huadong Medicine Oral Weight Loss Drug Product and Services
9.12.4 Huadong Medicine Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Huadong Medicine Recent Developments/Updates
9.12.6 Huadong Medicine Competitive Strengths & Weaknesses
9.13 Innovent Biologics
9.13.1 Innovent Biologics Details
9.13.2 Innovent Biologics Major Business
9.13.3 Innovent Biologics Oral Weight Loss Drug Product and Services
9.13.4 Innovent Biologics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Innovent Biologics Recent Developments/Updates
9.13.6 Innovent Biologics Competitive Strengths & Weaknesses
9.14 Ascletis Pharma
9.14.1 Ascletis Pharma Details
9.14.2 Ascletis Pharma Major Business
9.14.3 Ascletis Pharma Oral Weight Loss Drug Product and Services
9.14.4 Ascletis Pharma Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Ascletis Pharma Recent Developments/Updates
9.14.6 Ascletis Pharma Competitive Strengths & Weaknesses
9.15 Hansoh Pharmaceutical
9.15.1 Hansoh Pharmaceutical Details
9.15.2 Hansoh Pharmaceutical Major Business
9.15.3 Hansoh Pharmaceutical Oral Weight Loss Drug Product and Services
9.15.4 Hansoh Pharmaceutical Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Hansoh Pharmaceutical Recent Developments/Updates
9.15.6 Hansoh Pharmaceutical Competitive Strengths & Weaknesses
9.16 Kailera Therapeutics
9.16.1 Kailera Therapeutics Details
9.16.2 Kailera Therapeutics Major Business
9.16.3 Kailera Therapeutics Oral Weight Loss Drug Product and Services
9.16.4 Kailera Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

9.16.5 Kailera Therapeutics Recent Developments/Updates
9.16.6 Kailera Therapeutics Competitive Strengths & Weaknesses
9.17 Shionogi & Co
9.17.1 Shionogi & Co Details
9.17.2 Shionogi & Co Major Business
9.17.3 Shionogi & Co Oral Weight Loss Drug Product and Services
9.17.4 Shionogi & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Shionogi & Co Recent Developments/Updates
9.17.6 Shionogi & Co Competitive Strengths & Weaknesses
9.18 Haleon
9.18.1 Haleon Details
9.18.2 Haleon Major Business
9.18.3 Haleon Oral Weight Loss Drug Product and Services
9.18.4 Haleon Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Haleon Recent Developments/Updates
9.18.6 Haleon Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Oral Weight Loss Drug Industry Chain
10.2 Oral Weight Loss Drug Upstream Analysis
10.3 Oral Weight Loss Drug Midstream Analysis
10.4 Oral Weight Loss Drug Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Oral Weight Loss Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Oral Weight Loss Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Oral Weight Loss Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Oral Weight Loss Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Oral Weight Loss Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oral Weight Loss Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Oral Weight Loss Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Oral Weight Loss Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Oral Weight Loss Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Oral Weight Loss Drug Players in 2025
Table 12. World Oral Weight Loss Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Oral Weight Loss Drug Company Evaluation Quadrant
Table 14. Head Office of Key Oral Weight Loss Drug Players
Table 15. Oral Weight Loss Drug Market: Company Product Type Footprint
Table 16. Oral Weight Loss Drug Market: Company Product Application Footprint
Table 17. Oral Weight Loss Drug Mergers & Acquisitions Activity
Table 18. United States VS China Oral Weight Loss Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Oral Weight Loss Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Oral Weight Loss Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oral Weight Loss Drug Revenue, (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 22. United States Based Companies Oral Weight Loss Drug Revenue Market Share (2021-2026)
Table 23. China Based Oral Weight Loss Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oral Weight Loss Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Oral Weight Loss Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Oral Weight Loss Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Oral Weight Loss Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Oral Weight Loss Drug Revenue Market Share (2021-2026)
Table 29. World Oral Weight Loss Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Oral Weight Loss Drug Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Oral Weight Loss Drug Market Size by Type (2027-2032) & (USD Million)
Table 32. World Oral Weight Loss Drug Market Size by Ingredient, (USD Million), 2021 & 2025 & 2032
Table 33. World Oral Weight Loss Drug Market Size Value by Ingredient (2021-2026) & (USD Million)
Table 34. World Oral Weight Loss Drug Market Size by Ingredient (2027-2032) & (USD Million)
Table 35. World Oral Weight Loss Drug Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 36. World Oral Weight Loss Drug Market Size Value by Dosage Form (2021-2026) & (USD Million)
Table 37. World Oral Weight Loss Drug Market Size by Dosage Form (2027-2032) & (USD Million)
Table 38. World Oral Weight Loss Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Oral Weight Loss Drug Market Size by Application (2021-2026) & (USD Million)
Table 40. World Oral Weight Loss Drug Market Size by Application (2027-2032) & (USD Million)
Table 41. Novo Nordisk Basic Information, Manufacturing Base and Competitors

+357 96 030922
info@marketpublishers.com

Table 42. Novo Nordisk Major Business
Table 43. Novo Nordisk Oral Weight Loss Drug Product and Services
Table 44. Novo Nordisk Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novo Nordisk Recent Developments/Updates
Table 46. Novo Nordisk Competitive Strengths & Weaknesses
Table 47. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 48. Eli Lilly Major Business
Table 49. Eli Lilly Oral Weight Loss Drug Product and Services
Table 50. Eli Lilly Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Eli Lilly Recent Developments/Updates
Table 52. Eli Lilly Competitive Strengths & Weaknesses
Table 53. Currax Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 54. Currax Pharmaceuticals Major Business
Table 55. Currax Pharmaceuticals Oral Weight Loss Drug Product and Services
Table 56. Currax Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Currax Pharmaceuticals Recent Developments/Updates
Table 58. Currax Pharmaceuticals Competitive Strengths & Weaknesses
Table 59. VIVUS Basic Information, Manufacturing Base and Competitors
Table 60. VIVUS Major Business
Table 61. VIVUS Oral Weight Loss Drug Product and Services
Table 62. VIVUS Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. VIVUS Recent Developments/Updates
Table 64. VIVUS Competitive Strengths & Weaknesses
Table 65. Roche Basic Information, Manufacturing Base and Competitors
Table 66. Roche Major Business
Table 67. Roche Oral Weight Loss Drug Product and Services
Table 68. Roche Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Roche Recent Developments/Updates
Table 70. Roche Competitive Strengths & Weaknesses
Table 71. Structure Therapeutics Basic Information, Manufacturing Base and Competitors
Table 72. Structure Therapeutics Major Business
Table 73. Structure Therapeutics Oral Weight Loss Drug Product and Services

+357 96 030922
info@marketpublishers.com

Table 74. Structure Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Structure Therapeutics Recent Developments/Updates
Table 76. Structure Therapeutics Competitive Strengths & Weaknesses
Table 77. Viking Therapeutics Basic Information, Manufacturing Base and Competitors
Table 78. Viking Therapeutics Major Business
Table 79. Viking Therapeutics Oral Weight Loss Drug Product and Services
Table 80. Viking Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Viking Therapeutics Recent Developments/Updates
Table 82. Viking Therapeutics Competitive Strengths & Weaknesses
Table 83. Terns Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 84. Terns Pharmaceuticals Major Business
Table 85. Terns Pharmaceuticals Oral Weight Loss Drug Product and Services
Table 86. Terns Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Terns Pharmaceuticals Recent Developments/Updates
Table 88. Terns Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 90. AstraZeneca Major Business
Table 91. AstraZeneca Oral Weight Loss Drug Product and Services
Table 92. AstraZeneca Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. AstraZeneca Recent Developments/Updates
Table 94. AstraZeneca Competitive Strengths & Weaknesses
Table 95. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 96. Merck & Co Major Business
Table 97. Merck & Co Oral Weight Loss Drug Product and Services
Table 98. Merck & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Merck & Co Recent Developments/Updates
Table 100. Merck & Co Competitive Strengths & Weaknesses
Table 101. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 102. Jiangsu Hengrui Pharmaceuticals Major Business
Table 103. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product and Services
Table 104. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue, Gross

+357 96 030922
info@marketpublishers.com

Margin and Market Share (2021-2026) & (USD Million)
Table 105. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 106. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 107. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 108. Huadong Medicine Major Business
Table 109. Huadong Medicine Oral Weight Loss Drug Product and Services
Table 110. Huadong Medicine Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Huadong Medicine Recent Developments/Updates
Table 112. Huadong Medicine Competitive Strengths & Weaknesses
Table 113. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 114. Innovent Biologics Major Business
Table 115. Innovent Biologics Oral Weight Loss Drug Product and Services
Table 116. Innovent Biologics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Innovent Biologics Recent Developments/Updates
Table 118. Innovent Biologics Competitive Strengths & Weaknesses
Table 119. Ascletis Pharma Basic Information, Manufacturing Base and Competitors
Table 120. Ascletis Pharma Major Business
Table 121. Ascletis Pharma Oral Weight Loss Drug Product and Services
Table 122. Ascletis Pharma Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Ascletis Pharma Recent Developments/Updates
Table 124. Ascletis Pharma Competitive Strengths & Weaknesses
Table 125. Hansoh Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 126. Hansoh Pharmaceutical Major Business
Table 127. Hansoh Pharmaceutical Oral Weight Loss Drug Product and Services
Table 128. Hansoh Pharmaceutical Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Hansoh Pharmaceutical Recent Developments/Updates
Table 130. Hansoh Pharmaceutical Competitive Strengths & Weaknesses
Table 131. Kailera Therapeutics Basic Information, Manufacturing Base and Competitors
Table 132. Kailera Therapeutics Major Business
Table 133. Kailera Therapeutics Oral Weight Loss Drug Product and Services
Table 134. Kailera Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Kailera Therapeutics Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 136. Kailera Therapeutics Competitive Strengths & Weaknesses
Table 137. Shionogi & Co Basic Information, Manufacturing Base and Competitors
Table 138. Shionogi & Co Major Business
Table 139. Shionogi & Co Oral Weight Loss Drug Product and Services
Table 140. Shionogi & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Shionogi & Co Recent Developments/Updates
Table 142. Shionogi & Co Competitive Strengths & Weaknesses
Table 143. Haleon Basic Information, Manufacturing Base and Competitors
Table 144. Haleon Major Business
Table 145. Haleon Oral Weight Loss Drug Product and Services
Table 146. Haleon Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Haleon Recent Developments/Updates
Table 148. Haleon Competitive Strengths & Weaknesses
Table 149. Global Key Players of Oral Weight Loss Drug Upstream (Raw Materials)
Table 150. Global Oral Weight Loss Drug Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Oral Weight Loss Drug Picture
Figure 2. World Oral Weight Loss Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oral Weight Loss Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Oral Weight Loss Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Oral Weight Loss Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Oral Weight Loss Drug Revenue (2021-2032) & (USD Million)
Figure 13. Oral Weight Loss Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Oral Weight Loss Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Oral Weight Loss Drug Consumption Value (2021-2032) & (USD

+357 96 030922
info@marketpublishers.com

Million)
Figure 21. South Korea Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Oral Weight Loss Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Oral Weight Loss Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oral Weight Loss Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oral Weight Loss Drug Markets in 2025
Figure 27. United States VS China: Oral Weight Loss Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oral Weight Loss Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Oral Weight Loss Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Oral Weight Loss Drug Market Size Market Share by Type in 2025
Figure 31. GLP-1 Receptor Agonists
Figure 32. Gastrointestinal Lipase Inhibitors
Figure 33. Sympathomimetic Appetite Suppressants
Figure 34. Naltrexone/Bupropion Combination Drugs
Figure 35. Other
Figure 36. World Oral Weight Loss Drug Market Size Market Share by Type (2021-2032)
Figure 37. World Oral Weight Loss Drug Market Size by Ingredient, (USD Million), 2021 & 2025 & 2032
Figure 38. World Oral Weight Loss Drug Market Size Market Share by Ingredient in 2025
Figure 39. Single-Ingredient Drugs
Figure 40. Fixed-Dose Combination Drugs
Figure 41. World Oral Weight Loss Drug Market Size Market Share by Ingredient (2021-2032)
Figure 42. World Oral Weight Loss Drug Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 43. World Oral Weight Loss Drug Market Size Market Share by Dosage Form in 2025

+357 96 030922
info@marketpublishers.com

Figure 44. Immediate-Release Tablets
Figure 45. Extended-Release Tablets
Figure 46. Hard Capsules
Figure 47. Extended-Release Capsules
Figure 48. Other
Figure 49. World Oral Weight Loss Drug Market Size Market Share by Dosage Form (2021-2032)
Figure 50. World Oral Weight Loss Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Oral Weight Loss Drug Market Size Market Share by Application in 2025
Figure 52. dult Obesity
Figure 53. Adolescent Obesity
Figure 54. Short-Term Weight Reduction
Figure 55. Long-Term Chronic Weight Management
Figure 56. Other
Figure 57. World Oral Weight Loss Drug Market Size Market Share by Application (2021-2032)
Figure 58. Oral Weight Loss Drug Industrial Chain
Figure 59. Methodology
Figure 60. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Oral Weight Loss Drug Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GAA87163A4B4EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GAA87163A4B4EN.html